<DOC>
	<DOCNO>NCT01133210</DOCNO>
	<brief_summary>The purpose study determine effect maraviroc therapy obese insulin resistant subject : 1 . Plasma triglyceride concentration 2 . Plasma HDL-cholesterol LDL-cholesterol concentration 3 . Plasma marker cardiometabolic risk inflammation</brief_summary>
	<brief_title>Effect Maraviroc Metabolic Function Obese Subjects ( Phase I )</brief_title>
	<detailed_description>The purpose study determine , obese insulin resistant subject , effect maraviroc therapy , selective antagonist human chemokine receptor CCR5 , : 1 . Plasma triglyceride concentration 2 . Plasma HDL-cholesterol LDL-cholesterol concentration 3 . Plasma marker cardiometabolic risk inflammation</detailed_description>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>obese ( body mass index ( BMI ) 30 45.9 ) increase plasma triglyceride concentration ( 150400 mg/dL ) active previous infection hepatitis B C history alcohol abuse current alcohol consumption ( &gt; 20g/day ) severe hypertriglyceridemia ( &gt; 400 mg/dL ) active peptic ulcer disease diabetes pregnant lactate take statin , fibrates , niacin , moderate strong Cyp3A4 inhibitor inducer , medication might confound interpretation study result exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>hypertriglyceridemia</keyword>
	<keyword>triglyceride</keyword>
	<keyword>cholesterol</keyword>
	<keyword>Maraviroc</keyword>
</DOC>